PTAB Issues Guidance on Motions to Amend in View of Aqua Products
The Patent Trial and Appeal Board (“PTAB” or “Board”) recently issued guidance on motions to amend in AIA trial proceedings…
Current Public Availability of a Drug Label Does Not Demonstrate Public Availability at an Earlier Critical Date
In inter partes review (IPR) proceedings, petitioners bear the burden of demonstrating that documents relied on as printed publications were…
PTAB Issues Guidance on Remand Procedures
On November 15, 2017, the Patent Trial and Appeal Board (PTAB) published a revised Standard Operating Procedure 9 (“SOP 9”)…
AIA Trial Fees to Increase Substantially
On November 14, 2017, the United States Patent and Trademark Office (USPTO) published a final rule on fee increases that…